Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, allogeneic natural killer (NK) cell therapies. Its proprietary manufacturing and therapeutic platforms aim to treat severe, B-cell-driven autoimmune diseases and various forms of cancer by harnessing innate immune system responses combined with monoclonal antibodies.